Dendreon price target lowered to $.50 from $2.00 at Brean Capital

Brean Capital lowered its price target and reiterated its Sell rating on Dendreon following its Q3 earnings miss. The firm cited Provenge's inability to compete against other oral therapies, expectations for low adoption in Europe, and the prospects for the company running out of cash.

View Comments (1)